{"entity":{"id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","aka":[],"tldr":"A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang University, now recruiting.","summary":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT06770452 by Zhejiang University, with a registry enrolment figure of 133 participants, started 2025-03-25 and due to reach its primary completion in 2027-02-01. Interventions recorded: HRS-4642; Nimotuzumab; gemcitabine + nab-paclitaxel. Conditions listed: Metastatic Pancreatic Carcinoma. Primary outcome: Objective reponse rate (ORR). Pancreatic eligibility wording from the registry: \"Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer (from pancreatic ductal epithelium) for Arm B; 3\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06770452","url":"https://clinicaltrials.gov/study/NCT06770452"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["nimotuzumab","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06770452","phase":"2","setting":"A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations","sponsor":"Zhejiang University","enrolled":133,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06770452/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}